Clinical trials: Sepsis Syndrome
Bacteremia, Staphylococcus Aureus
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to…
- Conditions
- Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph
- Trial name
- diSArm (NCT05184764)
- Testing
- AP-SA02
- Where
- 28 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Sepsis, Sepsis Associated DIC
A Study to Learn About the Occurrence of Disseminated Intravascular Coagulation in People With Sepsis and Further Worsening of Sepsis
This is an exploratory study in which data from people with sepsis (a serious condition in which the body responds to an infection that damages vital organs) admitted to an Intensive care unit (ICU) who will receive treatment are…
- Trial name
- NCT06986798
- Testing
- Local standard medical care
- Where
- 31 sites in Austria, Belgium and 5 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Invasive Candidiasis, Candidemia
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
- Trial name
- NCT00189709
- Testing
- Micafungin, fluconazole
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Sepsis
A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.
- Trial name
- NCT00042588
- Testing
- Recombinant Chimeric Monoclonal Antibody
- Where
- United States
- Sponsor
- ICOS Corporation
Inpatient Hospitalization, Intensive Care Unit Admission, Inpatient Mortality, Sepsis and Septic Shock
Linking Novel Diagnostics With Data-Driven Clinical Decision Support in the Emergency Department
The primary objective of this study is to validate the use of an electronic clinical decision support (CDS) tool, TriageGO with Monocyte Distribution Width (TriageGO-MDW), in the emergency department (ED).
- Trial name
- NCT05335135
- Testing
- TriageGO-MDW Clinical Decision Support, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 300,000 people, healthy volunteers welcome
- Sponsor
- Stocastic, LLC
Severe Sepsis
Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05060250
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Bluejay Diagnostics, Inc.
Infection, Sepsis
Early Identification of SEPsis SIGNs in Emergency Department
Objective of SepSIGN project is to validate biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency Department.
- Trial name
- SepSIGN (NCT04261621)
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 815 people
- Sponsor
- BioMérieux
Severe Sepsis, Septic Shock
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
The two co-primary objectives of this study are to assess in Japanese patients with severe sepsis and/or septic shock: 1) the safety and tolerability of two different doses of intravenous AZD9773 and 2) the PK of AZD9773.
- Trial name
- NCT01144624
- Testing
- AZD9773
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
COVID-19
101-PGC-005 for the Treatment of COVID-19
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of…
- Trial name
- NCT05656521
- Testing
- 101-PGC-005, Dexamethasone
- Where
- 5 sites in India
- Volunteers
- 62 people
- Sponsor
- 101 Therapeutics
Severe Sepsis
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration [24 microgram/kilogram/hour (mcg/kg/hour) for 96 hours] or will…
- Trial name
- NCT00386425
- Testing
- Drotrecogin alfa (activated)
- Where
- 47 sites in United States, Belgium and 7 more
- Volunteers
- 486 people
- Sponsor
- Eli Lilly and Company
Sepsis
Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis
This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on ICU patients at…
- Trial name
- NCT04105699
- Testing
- Blood sampling
- Where
- 5 sites in United States
- Volunteers
- 544 people
- Sponsor
- Abionic SA
Severe Sepsis
S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT
The purpose of this study is to determine if Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) therapy is effective in the treatment of severe sepsis.
- Trial name
- SAFEbt (NCT01312675)
- Testing
- S.A.F.E.BT
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- B. Braun Medical Inc.
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Septic Shock
Early Albumin Resuscitation During Septic Shock
Objective: To determine whether the early administration of albumin as an expander and antioxidant would improve survival on the 28th day for septic shock patients.
- Trial name
- NCT00327704
- Testing
- albumin, saline
- Where
- France
- Volunteers
- 794 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Candidiasis, Invasive, Candidemia
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.
- Conditions
- Candidiasis, Invasive, Candidemia, Mycoses
- Trial name
- NCT00413218
- Testing
- Isavuconazole, Caspofungin, Voriconazole
- Where
- 113 sites in United States, Argentina and 23 more
- Volunteers
- 450 people
- Sponsor
- Astellas Pharma Inc
Drug Safety
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis.
- Trial name
- NCT01319903
- Testing
- CaCP29, a humanized monoclonal antibody
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- InflaRx GmbH
Sepsis, Infection
CV-SQuISH-ED: Clinical Validation Study
This is a study to evaluate the diagnostic performance of the investigational Cytovale System \& IntelliSep Test as a diagnostic marker of sepsis in a population of patients presenting to the emergency department with signs or…
- Trial name
- NCT04933760
- Testing
- Cytovale IntellipSep test
- Where
- 4 sites in United States
- Volunteers
- 599 people
- Sponsor
- Cytovale, Inc.
Severe Sepsis
Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis
Study will evaluate the safety and potential benefit of talactoferrin (recombinant human lactoferrin) as an addition to the standard care for severe sepsis.
- Trial name
- OASIS (NCT01273779)
- Testing
- Talactoferrin alfa
- Where
- 100 sites in United States, Belgium and 8 more
- Volunteers
- 1,280 people
- Sponsor
- Agennix
Severe Sepsis
Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis
Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.
- Trial name
- NCT00630656
- Testing
- Talactoferrin alfa
- Where
- 34 sites in United States, Canada and 3 more
- Volunteers
- 190 people
- Sponsor
- Agennix